Daniel A. Haber

Q: What Schools Are Affiliated With Daniel A. Haber

Daniel A. Haber is affiliated with the following schools: Massachusetts General Hospital, Heidelberg University, Harvard University, Kyoto Prefectural University of Medicine, Tohoku University, University of California, Los Angeles, Stanford University, Massachusetts Institute of Technology, Johns Hopkins University

Daniel A. Haber's AcademicInfluence.com Rankings

Daniel A. Haber

Philosophy

#3966

World Rank

#6311

Historical Rank

Logic

#1534

World Rank

#2311

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Daniel A. Haber's Degrees

Doctorate Medicine Harvard University

Why Is Daniel A. Haber Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Daniel A. Haber is the director of the Massachusetts General Hospital Cancer Center, a professor of oncology at Harvard Medical School, and an investigator of the Howard Hughes Medical Institute . Career Haber earned his B.S. in life sciences and M.S. in toxicology from Massachusetts Institute of Technology, and his M.D. and Ph.D. in biophysics from Stanford University School of Medicine under the mentorship of Robert T. Schimke. He did his postdoctoral training at Massachusetts Institute of Technology with David E. Housman.

(See a Problem?)

Daniel A. Haber's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. (2004) (10991)
DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development (1999) (5719)
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. (2010) (3445)
Isolation of rare circulating tumour cells in cancer patients by microchip technology (2007) (3343)
Epidermal growth factor receptor mutations in lung cancer (2007) (2842)
Systematic identification of genomic markers of drug sensitivity in cancer cells (2012) (2134)
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells (2012) (1904)
hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization (1997) (1879)
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition (2013) (1854)
Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus (1990) (1813)
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis (2014) (1786)
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (2004) (1596)
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip (2010) (1506)
Detection of mutations in EGFR in circulating lung-cancer cells. (2008) (1334)
A Landscape of Pharmacogenomic Interactions in Cancer (2016) (1254)
Circulating tumor cells: approaches to isolation and characterization (2011) (1009)
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. (1999) (979)
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. (2004) (961)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. (2005) (940)
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells (2013) (938)
Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome (1991) (914)
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway (2017) (911)
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon (2006) (893)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. (2008) (845)
salvador Promotes Both Cell Cycle Exit and Apoptosis in Drosophila and Is Mutated in Human Cancer Cell Lines (2002) (827)
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility (2014) (789)
Heterozygous Germline Mutations in the p53 Homolog p63 Are the Cause of EEC Syndrome (1999) (708)
Dual Role for Argonautes in MicroRNA Processing and Posttranscriptional Regulation of MicroRNA Expression (2007) (676)
BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function (2001) (674)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. (2005) (618)
Microfluidic, marker-free isolation of circulating tumor cells from blood samples (2014) (608)
Alternative splicing and genomic structure of the Wilms tumor gene WT1. (1991) (604)
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance (2015) (597)
Induction of GADD45 and JNK/SAPK-Dependent Apoptosis following Inducible Expression of BRCA1 (1999) (595)
An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor (1990) (586)
A microfluidic device for label-free, physical capture of circulating tumor cell-clusters (2015) (568)
Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. (2014) (552)
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib (2006) (549)
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents (2010) (536)
Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer (2010) (516)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. (2007) (516)
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 (2006) (513)
Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. (1998) (511)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. (2008) (511)
Correlating chemical sensitivity and basal gene expression reveals mechanism of action (2015) (500)
A recurrent mutation in PALB2 in Finnish cancer families (2007) (475)
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR (2005) (472)
Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines (2001) (466)
REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. (2002) (457)
Aberrant Overexpression of Satellite Repeats in Pancreatic and Other Epithelial Cancers (2011) (456)
Expression of the Wilms' tumor gene WT1 in the murine urogenital system. (1991) (443)
WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour (1991) (443)
Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase (1998) (440)
Exon amplification: a strategy to isolate mammalian genes based on RNA splicing. (1991) (421)
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. (2008) (416)
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. (2011) (410)
RNA sequencing of pancreatic circulating tumour cells implicates WNT signaling in metastasis (2012) (406)
Single-Cell RNA Sequencing Identifies Extracellular Matrix Gene Expression by Pancreatic Circulating Tumor Cells (2014) (404)
Expression of TERT in early premalignant lesions and a subset of cells in normal tissues (1998) (404)
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. (1996) (400)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine (2010) (391)
YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway (2009) (390)
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors (2015) (373)
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer (2017) (365)
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling (2007) (353)
Clusters of circulating tumor cells traverse capillary-sized vessels (2016) (344)
Heterozygous ATM mutations do not contribute to early onset of breast cancer (1997) (343)
WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. (1995) (335)
Wilms' tumour: connecting tumorigenesis and organ development in the kidney (2005) (326)
An X Chromosome Gene, WTX, Is Commonly Inactivated in Wilms Tumor (2007) (326)
The Wilms Tumor Suppressor WT1 Encodes a Transcriptional Activator of amphiregulin (1999) (322)
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families (1996) (313)
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses (2015) (312)
Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer (2019) (308)
Pharmacogenomic agreement between two cancer cell line data sets (2015) (306)
HER2 expression identifies dynamic functional states within circulating breast cancer cells (2016) (304)
Circulating tumor cells: a window into cancer biology and metastasis. (2010) (302)
Physical and functional interaction between WT1 and p53 proteins. (1993) (295)
Wilms tumor and the WT1 gene. (2001) (280)
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair / fair skin background (2012) (277)
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. (2012) (275)
A conduit to metastasis: circulating tumor cell biology (2017) (268)
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells (2017) (261)
Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development (1991) (258)
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers (2012) (257)
Integrating genomic features for non-invasive early lung cancer detection (2020) (257)
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. (2006) (256)
The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. (1995) (254)
A UV-independent pathway to melanoma carcinogenesis in the redhair-fairskin background (2012) (252)
A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1 (1996) (252)
Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. (2008) (252)
DOCK4, a GTPase Activator, Is Disrupted during Tumorigenesis (2003) (235)
Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. (1997) (221)
The Evolving War on Cancer (2011) (218)
Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. (1996) (210)
En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition. (2015) (208)
The Wilms tumour gene WT1 is expressed in murine mesoderm–derived tissues and mutated in a human mesothelioma (1993) (207)
The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor (2008) (206)
Brain tumor cells in circulation are enriched for mesenchymal gene expression. (2014) (193)
Cancer: Drivers and passengers (2007) (190)
Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. (1981) (187)
Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. (2006) (187)
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. (2007) (185)
Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. (2001) (180)
The Wilms tumor suppressor WT1 directs stage‐specific quiescence and differentiation of human hematopoietic progenitor cells (2001) (178)
WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin (2001) (177)
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. (2007) (176)
The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. (2009) (175)
Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. (2001) (173)
WT1-mediated Transcriptional Activation Is Inhibited by Dominant Negative Mutant Proteins (*) (1995) (171)
Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT. (1991) (165)
WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. (1993) (165)
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents (2001) (165)
Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas (2006) (162)
Tumour-suppressor genes: evolving definitions in the genomic age (1997) (161)
The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour (1997) (159)
Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort (2008) (157)
Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. (2001) (156)
Splicing into Senescence: The Curious Case of p16 and p19ARF (1997) (153)
Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish (2019) (152)
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. (2007) (150)
Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. (1995) (150)
Collective and Individual Migration following the Epithelial-Mesenchymal Transition (2014) (149)
Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis (2020) (144)
Microfluidic Isolation of Circulating Tumor Cell Clusters by Size and Asymmetry (2017) (143)
Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR (2005) (142)
Tunable Nanostructured Coating for the Capture and Selective Release of Viable Circulating Tumor Cells (2015) (141)
The Tre2 (USP6) oncogene is a hominoid-specific gene (2003) (141)
Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour (1993) (134)
The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis (2013) (131)
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma (2013) (131)
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. (2018) (130)
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy (2014) (129)
A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. (2009) (127)
Pericentromeric satellite repeat expansions through RNA-derived DNA intermediates in cancer (2015) (124)
Induction of p21 by the Wilms' tumor suppressor gene WT1. (1997) (124)
An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma (2017) (119)
P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells. (2003) (117)
“Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation (2006) (114)
Genetic events in the development of Wilms' tumor. (1994) (114)
The EWS-WT1 gene fusion in desmoplastic small round cell tumor. (2005) (112)
Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer. (2019) (111)
Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. (2005) (107)
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. (2009) (107)
Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70. (1998) (103)
Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells (2017) (103)
Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase (2014) (102)
Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites (2008) (99)
A highly conserved processed PTEN pseudogene is located on chromosome band 9p21 (1998) (99)
Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. (2000) (96)
An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. (2018) (94)
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy (2018) (93)
SUMO modification is required for in vivo Hox gene regulation by the Caenorhabditis elegans Polycomb group protein SOP-2 (2004) (91)
Isolation and molecular characterization of circulating melanoma cells. (2014) (90)
Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome. (1992) (90)
Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy. (2015) (90)
A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration. (2010) (90)
The Drosophila ATM Ortholog, dATM, Mediates the Response to Ionizing Radiation and to Spontaneous DNA Damage during Development (2004) (89)
Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. (2002) (89)
Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses (2011) (87)
A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases (2013) (87)
Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes (1981) (86)
Dynamic Chromatin Modification Sustains Epithelial-Mesenchymal Transition following Inducible Expression of Snail-1 (2013) (86)
Biopolymer system for cell recovery from microfluidic cell capture devices. (2012) (85)
Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients (2006) (84)
Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition. (2016) (84)
The promise of cancer genetics (1998) (84)
Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination (2017) (82)
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. (2010) (81)
Microfluidic isolation of platelet-covered circulating tumor cells. (2017) (80)
Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. (2010) (78)
Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. (2000) (78)
Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. (2008) (77)
Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis. (2002) (77)
The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity (2009) (73)
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts (2007) (73)
Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer (1998) (73)
Continuous Flow Microfluidic Bioparticle Concentrator (2015) (71)
Increased Prevalence of EGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms (2008) (70)
BRCA1 Regulates the Interferon γ-mediated Apoptotic Response* (2002) (67)
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. (2018) (67)
Structural rearrangements of the WT1 gene in Wilms' tumour cells. (1991) (66)
Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. (1999) (65)
Biodegradable nano-films for capture and non-invasive release of circulating tumor cells. (2015) (65)
Ultrahigh-throughput magnetic sorting of large blood volumes for epitope-agnostic isolation of circulating tumor cells (2020) (65)
Familial predisposition to Wilms tumor does not segregate with the WT1 gene. (1991) (63)
The C. elegans Polycomb gene SOP-2 encodes an RNA binding protein. (2004) (62)
The WTX tumor suppressor enhances p53 acetylation by CBP/p300. (2012) (61)
The lipogenic regulator SREBF2 induces Transferrin in circulating melanoma cells and suppresses ferroptosis. (2020) (61)
Corrigendum: RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis (2012) (60)
Amplification-free digital gene expression profiling from minute cell quantities (2010) (59)
Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: Evidence for common founders and independent mutations (1998) (59)
The genetics of Wilms' tumor. (1992) (58)
Transcriptional Activation of Placental Growth Factor by the Forkhead/Winged Helix Transcription Factor FoxD1 (2003) (57)
Cancer metastasis through the prism of epithelial‐to‐mesenchymal transition in circulating tumor cells (2017) (56)
Primary gastrointestinal lymphoma. (1988) (56)
Global regulation of Hox gene expression in C. elegans by a SAM domain protein. (2003) (55)
Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma (2019) (55)
Cell density dependence of focus formation in the C3H/10T1/2 transformation assay. (1977) (55)
Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast. (1997) (54)
Hereditary breast cancer. (1998) (53)
Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein. (2003) (53)
Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment (2008) (52)
The tumor suppressor gene WT1 inhibits ras-mediated transformation. (1995) (51)
E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells (1998) (51)
A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells. (1992) (51)
RNA transcripts stimulate homologous recombination by forming DR-loops (2021) (50)
Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. (2005) (50)
Yeast, flies, worms, and fish in the study of human disease. (2003) (50)
Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models. (2014) (50)
Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents (2006) (49)
The WTX tumor suppressor regulates mesenchymal progenitor cell fate specification. (2011) (49)
Modeling oncogene addiction using RNA interference (2008) (47)
A Functional Interaction with CBP Contributes to Transcriptional Activation by the Wilms Tumor Suppressor WT1* (2001) (47)
Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. (2006) (47)
Induction of the interleukin-2/15 receptor β-chain by the EWS–WT1 translocation product (2002) (46)
AR Expression in Breast Cancer CTCs Associates with Bone Metastases (2018) (46)
WT1: a novel tumor suppressor gene inactivated in Wilms' tumor. (1992) (46)
SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes (2015) (46)
Rate-limiting steps: The genetics of pediatric cancers (1991) (46)
WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. (1995) (46)
Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target (2020) (46)
BRCA1 regulates the interferon gamma-mediated apoptotic response. (2002) (44)
SUMO-1 Modification of the Wilms’ Tumor Suppressor WT1 (2004) (44)
A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12 (2013) (44)
Adenosine Transporter ENT4 Is a Direct Target of EWS/WT1 Translocation Product and Is Highly Expressed in Desmoplastic Small Round Cell Tumor (2008) (44)
Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells (2017) (42)
MAPK7 Regulates EMT Features and Modulates the Generation of CTCs (2015) (42)
Cancer detection: Seeking signals in blood (2018) (42)
A Rap GTPase interactor, RADIL, mediates migration of neural crest precursors. (2007) (41)
Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor (2000) (40)
Common nonsense mutations in RAD52. (1999) (40)
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways (2015) (39)
Functional properties of WT1. (1996) (38)
Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity. (2016) (38)
Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. (2002) (37)
Abstract 1136: Detection and characterization of circulating tumor cells in localized and metastatic prostate cancer patients using CTC-Chip microfluidic technology (2010) (35)
Role of the WT1 gene in Wilms' tumour. (1992) (34)
HIF1A signaling selectively supports proliferation of breast cancer in the brain (2020) (34)
The Role of Physical Stabilization in Whole Blood Preservation (2016) (34)
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment (2015) (34)
Cascades of transcriptional induction during human lymphocyte activation. (2001) (34)
Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor. (1993) (33)
Clusters of Circulating Tumor Cells: a Biophysical and Technological Perspective. (2017) (33)
Roads leading to breast cancer. (2000) (33)
SETD1A protects from senescence through regulation of the mitotic gene expression program (2019) (32)
A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. (2016) (32)
Will radioiodine be useful in treatment of breast cancer? (2000) (31)
Telomeres, cancer, and immortality. (1995) (30)
Developing Standards for Breakthrough Therapy Designation in Oncology (2013) (29)
The Predominant WT1 Isoform (+KTS) Encodes a DNA-Binding Protein Targeting the Planar Cell Polarity Gene Scribble in Renal Podocytes (2010) (29)
Characterization of three overlapping deletions causing X-linked lymphoproliferative disease. (1993) (28)
Microfluidic concentration and separation of circulating tumor cell clusters from large blood volumes. (2020) (28)
Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker. (1993) (26)
Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease. (2018) (25)
Cell fate: Transition loses its invasive edge (2015) (25)
Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer: Predicting Clinical Response to Kinase Inhibitors (2005) (25)
COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis (2019) (25)
Childhoood cancer predisposition: Applications of molecular testing and future implications (1998) (25)
Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials (2005) (23)
Mutation analysis of the hCHK2 gene in primary human malignant gliomas (2000) (23)
Solidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer? (2014) (22)
A computational study of circulating large tumor cells traversing microvessels (2015) (21)
A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells (2018) (21)
Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms (2017) (21)
Alternative splicing and genomic structure of the Wilms tumor gene WT 1 ( alternative splicing / genomic structure (20)
Overcoming Acquired Resistance to Iressa/Tarceva with Inhibitors of a Different Class (2005) (18)
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer (2019) (18)
Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. (2006) (18)
Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk (2003) (18)
Rbm19 is a nucleolar protein expressed in crypt/progenitor cells of the intestinal epithelium. (2005) (17)
The BRCA2-EMSY Connection Implications for Breast and Ovarian Tumorigenesis (2003) (16)
Physical Map and Cosmid Contig Encompassing a New Interstitial Deletion of the X-Linked Lymphoproliferative Syndrome Region (1996) (15)
Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin (2009) (15)
Childhood cancer predisposition: applications of molecular testing and future implications. (1998) (14)
The WTX Tumor Suppressor Interacts with the Transcriptional Corepressor TRIM28* (2015) (14)
Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene (2007) (13)
Molecular genetics of Wilms tumor. (1995) (13)
Translational Regulation of Cancer Metastasis (2021) (13)
Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum. (1999) (11)
Abstract LB-174: Translation of preclinical predictive sensitivity of Ewing sarcoma to PARP inhibition: Phase II study of olaparib in adult patients with recurrent/metastatic Ewing sarcoma following failure of prior chemotherapy. (2013) (11)
Pulmonary adenocarcinomas with mutant epidermal growth factor receptors. (2005) (10)
Identification of genetically aberrant cell lineages in Wilms' tumors (1994) (10)
A Blood-Based Test for Epidermal Growth Factor Receptor Mutations in Lung Cancer (2006) (10)
BRCA1: an emerging role in the cellular response to DNA damage (2000) (10)
RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. (2004) (10)
In-flow measurement of cell-cell adhesion using oscillatory inertial microfluidics. (2020) (10)
The 1100delAT BRCA1 and the 8765delAG BRCA2 Mutations: Occurrence in High-Risk Non-Ashkenazi Jews and Haplotype Comparison of Jewish and Non-Jewish Carriers (2004) (10)
Preservative solution that stabilizes erythrocyte morphology and leukocyte viability under ambient conditions (2017) (10)
Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. (2011) (10)
Highly Multiplexed Fluorescence in Situ Hybridization for in Situ Genomics. (2019) (9)
Inactivation of the tumor suppressor WTX in a subset of pediatric tumors (2014) (9)
Chromosome-mediated transfer and amplification of an altered mouse dihydrofolate reductase gene (1982) (9)
Genomics of Drug Sensitivity in Cancer (GDSC): A resource for biomarker discovery in cancer cells (2016) (9)
Isolation of circulating tumor cells (2022) (9)
Morphological transformation of C3H/10T1/2 cells subcultured at low cell densities. (1978) (9)
ATRAID regulates the action of nitrogen-containing bisphosphonates on bone (2020) (9)
Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer (2020) (8)
An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients (2009) (7)
Abstract LB-427: TAK1 (MAP3K7) inhibition promotes apoptosis in KRAS dependent colon cancers (2012) (7)
Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC). (2018) (7)
NR4A1 regulates expression of immediate early genes, suppressing replication stress in cancer. (2021) (7)
Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. (2016) (7)
Modeling background radiation using geochemical data: A case study in and around Cameron, Arizona. (2016) (6)
Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA (2021) (6)
Fantastic voyage: the future of cancer diagnostics. (2015) (6)
Ultra-fast vitrification of patient-derived circulating tumor cell lines (2018) (6)
Dual role for Argonaute proteins in microRNA processing and regulation (2007) (6)
Abstract CT048: Phase 1/2 study of olaparib tablets and temozolomide in patients with small cell lung cancer (SCLC) following failure of prior chemotherapy (2017) (6)
Basic Principles of Cancer Genetics (2010) (5)
Single Cell RNA Profiling of Circulating Tumor Cells in Patients With Prostate Cancer (2015) (5)
Relationship between hepatocellular carcinoma circulating tumor cells and tumor volume (2018) (5)
Does molecular monitoring matter in early-stage breast cancer? (2015) (5)
Stott with Localized and Metastatic Prostate Cancer Isolation and Characterization of Circulating Tumor Cells from Patients (2010) (5)
SETD 1 A modulates cell cycle progression through a miRNA network that regulates p 53 target genes (2015) (4)
Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases. (2012) (4)
Abstract A75: Circulating tumor cells in human breast cancer exhibit dynamic changes in epithelial and mesenchymal composition (2013) (4)
Liquid Biopsy in Hepatocellular Carcinoma (2019) (3)
Case–control analysis identifies shared properties of rare germline variation in cancer predisposing genes (2019) (3)
Modeling background radiation in Southern Nevada. (2017) (3)
ATRAID, a genetic factor that regulates the clinical action of nitrogen-containing bisphosphonates on bone (2018) (3)
MspI/HpaII polymorphism in the human multidrug resistance gene 1. (1989) (3)
Subsurface Flows Near Active Regions and Filaments as Determined by Local Helioseismology (2008) (3)
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 28-2003. A 51-year-old premenopausal woman with newly diagnosed breast cancer and a strong family history of breast cancer. (2003) (3)
Abstract NG04: Diversity of circulating tumor cells in a mouse pancreatic cancer model identified by single cell RNA sequencing (2014) (3)
Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients. (2013) (3)
Prevalence of ataxia-telangiectasia heterozygosity in patients developing contralateral breast cancer following treatment with conservative surgery and radiation therapy (1998) (3)
PD-156 The Massachusetts General Hospital/Dana-Farber Cancer Institute/Harvard Medical School Partners HealthCare Center for genetics and genomics experience with clinical testing for somatic EGFR mutations in NSCLC patients (2005) (2)
A landscape of synergistic drug combinations in non-small-cell lung cancer (2021) (2)
Integrated Gene Expression Score in Circulating Tumor Cells to Predict Treatment Response in Muscle-Invasive Bladder Cancer (2019) (2)
SETD1A protects from senescence through regulation of the mitotic gene expression program (2019) (2)
Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody (2022) (2)
Abstract 2679: Induction of β-globin protects circulating tumor cells from oxidative stress during dissemination (2016) (2)
Abstract OT2-03-03: Evaluation of talazoparib, a PARP inhibitor, in patients with somaticBRCAmutant metastatic breast cancer: Genotyping based clinical trial (2020) (2)
Circulating Tumor Cells and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer (2020) (2)
Activating mutations in the epidermal growth factor receptor underlie responsiveness of non-small cell lung cancer to the tyrosine kinase inhibitor Gefitinib (2005) (2)
In vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2 (2008) (2)
Case–control analysis identifies shared properties of rare germline variation in cancer predisposing genes (2018) (2)
Abstract 4004: Molecular characterization of circulating glioblastoma cells identifies a mesenchymal-like tumor cell subpopulation (2014) (2)
Abstract 4568: Rapid assessment of TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF mutant melanoma. (2013) (2)
Analyses of circulating tumor cell (CTC) dynamics and treatment response in prostate cancer using the CTC-chip microfluidic device. (2009) (2)
Evaluation of autotransfusion during resection of colorectal carcinoma liver metastases (CRCLM): are circulating tumor cells (CTCs) a problem? (2014) (2)
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy (2014) (1)
35 The Genomics of Drug Sensitivity in Cancer (2012) (1)
A method for determining the responsiveness of a tumor to treatments with the epidermal growth factor receptor as a target (2005) (1)
67 Molecular Characterization of Circulating Tumour Cells (2012) (1)
Novel Agents in theTreatment of Lung Cancer : Advances in EGFR-Targeted Agents (2006) (1)
Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib (2022) (1)
PD-145 Long-term survival of NSCLC patients with EGFR mutationstreated with EGFR TKIs gefitinib or erlotinib (2005) (1)
A Strategy for Large-Scale Systematic Pan-Cancer Germline Rare Variation Analysis (2017) (1)
breast cancer progression A developmentally regulated inducer of EMT , LBX 1 , contributes to Material Supplemental (2009) (1)
Monte Carlo simulations of the gamma-ray exposure rates of common rocks. (2017) (1)
Single molecule RNA sequencing of formalin-fixed paraffin-embedded tissue derived from patients with lung cancer. (2011) (1)
Combined Blockade of PI3K/AKT and EGFR/HER3 Enhances Anti-Tumor Activity in Triple Negative Breast Cancer (2012) (1)
Systems Biology of Cancer: The role of growth factor-induced changes in cell fate in prostate cancer progression (2015) (1)
ArticleThe C . elegans Polycomb Gene sop-2 Encodes an RNA Binding Protein yeast (2004) (1)
Advances in Brief WT 1 Induces Expression of Insulin-like Growth Factor 2 in Wilms ' Tumor Cells ' (2006) (1)
Differential kinase activity across prostate tumor compartments defines sensitivity to target inhibition (2022) (1)
Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms (2018) (1)
Resource A Landscape of Pharmacogenomic Interactions in Cancer Graphical Abstract Highlights (2016) (1)
Abstract 4953: Single cell signaling analysis reveals circulating tumor cell markers of drug susceptibility and tumor heterogeneity (2017) (1)
Abstract IA09: Single cell RNA-sequencing of circulating tumor cells (2016) (1)
Abstract 4955: Isolation and characterization of circulating tumor cells (CTCs) in breast and prostate cancer: Comparison of Harpoon CTC assay performance with the CellSearch CTC Test (2016) (1)
A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells (2020) (1)
Abstract P4-01-06: Elacestrant (RAD1901) inhibits growth of ex vivo cultured circulating tumor cells derived from hormone receptor-positive metastatic breast cancer (mBC) patients including those harboring ESR1 mutations (2020) (1)
Modeling gamma radiation exposure rates using geologic and remote sensing data to locate radiogenic anomalies. (2019) (1)
Emre Ozkumur Sorting of Rare Circulating Tumor Cells Independent − Dependent and − Inertial Focusing for Tumor Antigen (2013) (1)
Abstract PL06-04: Molecular characterization of circulating tumor cells. (2013) (1)
Predictive Modeling of Terrestrial Radiation Exposure from Geologic Materials (2015) (1)
Integrating genomic features for non-invasive early lung cancer detection (2020) (0)
Aerial Measuring System Geophysical Calibration Longitudinal Study (2020) (0)
Predictive Radiological Background Distributions from Geologic Data (2015) (0)
Abstract 4584: A novel drug-eluting platform for localized treatment of pancreatic cancer (2014) (0)
Raffaella Sordella Anti-Apoptotic Pathways Mutations in Lung Cancer Activate EGFR Gefitinib-Sensitizing (2011) (0)
Impact of Noncoding Satellite Repeats on Pancreatic Cancer Metastasis (2015) (0)
Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells (2017) (0)
Single-Cell RNA Sequencing Identifies Extracellular Matrix Gene Expression by Pancreatic Circulating Tumor Cells Graphical (2014) (0)
Abstract 1410: Proliferation during epithelial-to-mesenchymal transition induces genomic instability (2017) (0)
Method for determining the response of cancer to treatments directed at the epidermal growth factor receptor (2005) (0)
Abstract 210: Uncovering a novel layer of complexity in the architecture of pancreatic cancer (2018) (0)
ABlood-BasedTest for Epidermal Growth Factor Receptor Mutations in Lung Cancer 55 (0)
Germline TP53 mutations in women with very early onset breast cancer (BR) (2005) (0)
Abstract SY24-01: High-throughput CTC detection for noninvasive cancer monitoring (2017) (0)
BRCA1 Regulates the Interferon (cid:1) -mediated Apoptotic Response* (2002) (0)
A novel role for BRCA1 in mediating the interferon gamma antiproliferative response (2002) (0)
Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells (2017) (0)
Chabner Colloquium: Answering the Big Questions in Cancer Research & 2018 STO Annual Meeting (2018) (0)
Abstract LB-192: Circulating tumor cell clusters are precursors of breast cancer metastasis (2014) (0)
Epidermal growth factor receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients (pts). (2016) (0)
Abstract 2203: Integrative analysis for efficient candidate oncogene discovery in cancer cell lines (2010) (0)
IMPACT Background Chordoma is a type of bone cancer affecting the spine and base of the skull (2014) (0)
Figure 5—source data 2. (2015) (0)
Abstract PR6: Why redheads are at increased risk of melanoma: A novel BRAF mutant mouse model (2011) (0)
BRCA1 mediated G2/M cell cycle arrest in response to taxol. (2000) (0)
American Brain Tumor Association Young Investigator Award 198 Circulating Tumor Cells in Patients With Glioblastoma (2014) (0)
Haber Processing Alterations in Predicted Secondary Structure Do Not Affect Sequence Variations of MicroRNAs in Human Cancer : Updated (2006) (0)
A Population-Based Treatment Margin for Respiratory Motion of Lung Tumors (2013) (0)
Advances in Brief Common Nonsense Mutations in RAD 52 1 (1999) (0)
Abstract 2446: Real-time molecular imaging of targeted therapies in patient-derived tumor cells by quantitative immunofluorescence microscopy (2012) (0)
O0036 COMMON FEATURES OF GUT DEVELOPMENT AND NEOPLASIA REFLECTED BY NPO GENE EXPRESSION (2004) (0)
Event Cancer screening Localized cancer Metastatic cancer Refractory cancer Treatment strategy Early intervention Multiple DNA abnormalities RNA expression and fusion transcripts (2014) (0)
Abstract LB-228: YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway (2009) (0)
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. (2023) (0)
Abstract C155: Inhibition of TAK1 promotes apoptosis in KRAS and Wnt pathway codependent colon cancers. (2011) (0)
Abstract 4773: Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6 dependent survival pathways (2014) (0)
Advances in Brief Altered fra / zs-Activational Properties of a Mutated WT 1 Gene Product in a WAGR-associated Wilms ' liimor 1 (2006) (0)
Prospective Evaluation of a Digital RNA Circulating Tumor Cell Signature in Localized Prostate Cancer (2018) (0)
Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation (2022) (0)
Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade (2023) (0)
Abstract 771: Mechanisms of genetic predisposition to multifocal lung cancer (2023) (0)
Connecting Aerial Gamma Ray Surveys and Geochemical Data (2014) (0)
AMS/DSA Joint Survey Report (2020) (0)
Abstract 2422: Isolation of canonical and non-canonical circulating tumor cells (CTCs) by negative depletion using the Harpoon CTC Isolator and Chip (2016) (0)
Abstract 1736: A novel RNA-based assay for the detection and monitoring of circulating tumor cell signatures in breast cancer (2017) (0)
Method for treating cancer resistant to gefitinib. (2006) (0)
MC13-0075 Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients (2013) (0)
A method for the treatment of gefitinib-resistant cancer (2006) (0)
Abstract 4349: The tumor suppressor WTX is inactivated in a subset of pediatric tumors (2011) (0)
853 Pharmacogenomic Profiling of Drugs in Cancer Cells Identifies Novel Biomarkers of Sensitivity (2012) (0)
Abstract 2473:NR4A1suppresses cancer replication stress through R-loop-dependent inhibition of immediate early gene transcriptional elongation (2021) (0)
Examining the Spatial Scale of Variations in Terrestrial Gamma-Ray Background Over Individual Bedrock Geologic Units. (2015) (0)
Transcapillary Trafficking of Clustered Circulating Tumor Cells (2015) (0)
Evaluating Variations in Uranium, Thorium and Potassium Content in the Pierre Shale using National Uranium Resource Evaluation Aerial Gamma-Ray Survey Data (2015) (0)
Preservative solution that stabilizes erythrocyte morphology and leukocyte viability under ambient conditions (2017) (0)
Altered fra/zs-Activational Properties of a Mutated WT1 Gene Product in a WAGR-associated Wilms' liimor1 (2006) (0)
4-D Aggregate Deconvolution for Aerial Measurements RSLN-026-20, Year 1 (2020) (0)
Abstract 1571: Novel microfluidic technology and biology based approach for isolation and characterization of circulating cells from the peripheral blood of patients with Lymphangioleiomyomatosis (2011) (0)
Award Number: W81XWH-13-1-0237 TITLE: IImpact of Noncoding Satellite Repeats on Pancreatic Cancer Metastasis PRINCIPAL INVESTIGATOR: David T. Ting, MD CONTRACTING ORGANIZATION: Massachusetts General Hospital (2015) (0)
Abstract 5757: A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers (2010) (0)
Pathogenesis of Wilms Tumor (2011) (0)
Single cell proteomics of tumor compartments identifies differential kinase activities defining sensitivity to mTOR-PI3-kinase inhibition (2021) (0)
Invited Papers (2002) (0)
RBM19 IS EXPRESSED IN THE STEM CELL COMPARTMENT OF THE INTESTINAL EPITHELIUM: 67 (2005) (0)
Abstract 2972: Co-clinical trial of olaparib and temozolomide in SCLC PDX models uncovers new biomarkers of sensitivity (2018) (0)
Relationship between hepatocellular carcinoma circulating tumor cells and tumor volume (2018) (0)
Erratum: Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (26835–26845) DOI: 10.1073/pnas.1914915116) (2020) (0)
Abstract 6073: The lipogenic regulatorSREBPinducesTransferrinin circulating melanoma cells, suppressing their susceptibility to ferroptosis (2020) (0)
NR4A1 suppresses cancer replication stress through R-loop-dependent inhibition of immediate early gene transcriptional elongation (2020) (0)
Supplemental Information Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition (2016) (0)
Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target (2020) (0)
Abstract IA010: Hypomethylation of immune-related loci contribute to prostate tumorigenesis (2023) (0)
TGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state. (2023) (0)
Quantitative Analysis of Circulating Tumor Cells Using RNA-Based Digital Scoring. (2020) (0)
Abstract 1053: A large cellular screen charting the landscape of synergistic drug combinations in lung cancer (2021) (0)
Abstract P2-01-14: circulating tumor cells in breast cancer exhibit dynamic changes in epithelial and mesenchymal cell composition (2012) (0)
Abstract ES12-2: Single cell analysis of circulating tumor cells (2022) (0)
Dihydrofolate Reductase Gene Amplification, Altered Dihydrofolate Reductase, and Methotrexate Resistance in Cultured 3T6 Cells Associated with Unstable Amplification of an Altered Dihydrofolate Reductase Gene (1982) (0)
Abstract IA18: Molecular signatures of circulating tumor cells (2020) (0)
Molecular targeted therapy of lung cancer (2006) (0)
Negative-Selection Enrichment of Circulating Tumor Cells from Peripheral Blood Using the Microfluidic CTC-iChip. (2022) (0)
Short Article The C. elegans Polycomb Gene sop-2 Encodes an RNA Binding Protein (2004) (0)
Abstract SY30-01: Molecular characterization of single circulating tumor cells. (2013) (0)
Abstract CN08-02: Molecular detection and characterization of circulating tumor cells (2018) (0)
Analysis of the 70-gene breast cancer prognosis signature in a general hospital population. (2007) (0)
Abstract 1734: Absolute quantification of circulating tumor cell RNA enables high specificity detection of hepatocellular carcinoma (2017) (0)
Abstract P2-05-10: Withdrawn (2018) (0)
Characterization of circulating tumor cells in prostate cancer patients (2012) (0)
Principles of clinical cancer genetics (2010) (0)
Microfluidic Isolation of Circulating Tumor Cell Clusters by Size and Asymmetry (2017) (0)
Predictive Modeling of Radiological Background Using Geochemistry (2014) (0)
Figure 2—source data 1. (2015) (0)
Feasibility of Gene Expression Signature Analysis in Prostate Cancer Biopsy Specimens to Predict Outcomes Following Radiation Therapy (2013) (0)
Table of Contents (1995) (0)
Abstract CT073: Efficacy of novel oral SERD elacestrant in fulvestrant-refractory hormone receptor-positive (HR+) breast cancer: a translational investigation (2023) (0)
Abstract 5304: RNA sequencing of circulating tumor cells implicates WNT signaling in pancreatic cancer metastasis (2012) (0)
Author response: Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways (2015) (0)

This paper list is powered by the following services:

Other Resources About Daniel A. Haber

en.wikipedia.org

What Schools Are Affiliated With Daniel A. Haber?

Daniel A. Haber is affiliated with the following schools:

Daniel A. Haber's Academic­Influence.com Rankings